Durable endothelium-mimicking coating for surface bioengineering cardiovascular stents

Ma, Qing; Shi, Xin; Tan, Xing; Wang, Rui; Xiong, Kaiqin; Maitz, Manfred F.; Cui, Yuanyuan; Hu, Zhangmei; Tu, Qiufen; Huang, Nan; Shen, Li; Yang, Zhilu

doi:10.1016/j.bioactmat.2021.05.009

Cited by 29 publications

(24 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1,21,22] and permanent intraluminal devices, [18,23] such as, stents. The two most com-mon stent systems differ in their expansion principles: Balloon dilatation [24,25] and self-expansion. [17,18] In comparative studies of these stents, self-expandable stents have been found to cause less tension and less damage to the vessel; [26] animal studies have shown the correlation between neointimal proliferation and arterial injury when using balloon-expandable stents.…”

Section: Discussionmentioning

confidence: 99%

Biodegradation and Immunological Parameters of Polyurethane‐Based Tissue Adhesive in Arterial Microvascular Anastomoses—A Long‐Term In Vivo Study

Modabber

Winnand

Goloborodko

et al. 2022

Macromolecular Bioscience

View full text Add to dashboard Cite

In microsurgical anastomosis, non‐synthetic fibrin‐based adhesives have predominantly shown superior properties to synthetic cyanoacrylates, but they have hardly any clinical application. This study aims to investigate the local and systemic effects of synthetically produced biodegradable adhesive VIVO when used in microsurgical anastomosis. VIVO is used in two different anastomosis procedures in the common carotid artery in a rat model: VIVO in addition to a temporary catheter (VIVO TC) and VIVO with a custom‐shaped memory nitinol stent (VIVO SM). Conventionally sutured anastomoses serve as controls (C). Tissue response is assessed by in vivo fluorescence imaging and histological examination. The systemic effects of biodegradation are measured using hematologic parameters and serum levels of transaminase activity and lactate dehydrogenase. Finally, the degree of local adhesion of the different anastomotic procedures is evaluated. Fluorescence imaging shows reduced inflammatory blood flow in the VIVO TC group. Histological analysis of the anastomosed vessels also reveals significantly more inflammation in C than in the two adhesive groups. The severity of VIVO adhesions proves acceptable, and no histotoxic effects of VIVO are detected. The data demonstrate that the synthetic tissue adhesive VIVO is a reliable and—compared to sutures—tissue‐friendly adhesive for microsurgical anastomoses.

show abstract

Section: Discussionmentioning

confidence: 99%

Biodegradation and Immunological Parameters of Polyurethane‐Based Tissue Adhesive in Arterial Microvascular Anastomoses—A Long‐Term In Vivo Study

Modabber

Winnand

Goloborodko

et al. 2022

Macromolecular Bioscience

View full text Add to dashboard Cite

show abstract

“…However, there have limited surface bioengineering strategies for polymeric devices as compared with the metal devices, possibly owing to the chemical inertness of biomedical polymer materials. To facilitate the surface functionalization of polymer material, in this study, a durable amine-containing coating [39] was performed on the surface of polyvinyl chloride (PVC, a conventional medical materials approved for manufacturing blood-contacting device) substrates or tubes. Then, the mussel-inspired adhesive bioclickable peptide was robust tethered on the PVC through catechol-amine reaction.…”

Section: Molecular Synthesis and Surfacementioning

confidence: 99%

Mussel-Inspired and Bioclickable Peptide Engineered Surface to Combat Thrombosis and Infection

Moosa

2022

Research

Self Cite

View full text Add to dashboard Cite

Thrombosis and infections are the two major complications associated with extracorporeal circuits and indwelling medical devices, leading to significant mortality in clinic. To address this issue, here, we report a biomimetic surface engineering strategy by the integration of mussel-inspired adhesive peptide, with bio-orthogonal click chemistry, to tailor the surface functionalities of tubing and catheters. Inspired by mussel adhesive foot protein, a bioclickable peptide mimic (DOPA)4-azide-based structure is designed and grafted on an aminated tubing robustly based on catechol-amine chemistry. Then, the dibenzylcyclooctyne (DBCO) modified nitric oxide generating species of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelated copper ions and the DBCO-modified antimicrobial peptide (DBCO-AMP) are clicked onto the grafted surfaces via bio-orthogonal reaction. The combination of the robustly grafted AMP and Cu-DOTA endows the modified tubing with durable antimicrobial properties and ability in long-term catalytically generating NO from endogenous s-nitrosothiols to resist adhesion/activation of platelets, thus preventing the formation of thrombosis. Overall, this biomimetic surface engineering technology provides a promising solution for multicomponent surface functionalization and the surface bioengineering of biomedical devices with enhanced clinical performance.

show abstract

“…The high chemical stability of the pAMDA coating maximizes the biological activity of heparin while continuing to release NO for up to a month. Therefore, the functionalized vascular stent exhibits a long-term physiological effect of mimicking the endothelium in inhibiting thrombosis, inflammation, and immunity, thereby effectively reducing in-stent restenosis [ 87 ].…”

Section: Application Of No-releasing Biomaterials Platforms In Cvd Tr...mentioning

confidence: 99%

Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease

Wang

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the first leading cause of death globally. Nitric oxide (NO) is an important signaling molecule that mediates diverse processes in the cardiovascular system, thereby providing a fundamental basis for NO-based therapy of CVD. At present, numerous prodrugs have been developed to release NO in vivo. However, the clinical application of these prodrugs still faces many problems, including the low payloads, burst release, and non-controlled delivery. To address these, various biomaterial-based platforms have been developed as the carriers to deliver NO to the targeted tissues in a controlled and sustained manner. This review aims to summarize recent developments of various therapeutic platforms, engineered to release NO for the treatment of CVD. In addition, two potential strategies to improve the effectiveness of existing NO therapy are also discussed, including the combination of NO-releasing platforms and either hydrogen sulfide-based therapy or stem cell therapy. Hopefully, some NO-releasing platforms may provide important therapeutic benefits for CVD.

show abstract

Durable endothelium-mimicking coating for surface bioengineering cardiovascular stents

Cited by 29 publications

References 55 publications

Biodegradation and Immunological Parameters of Polyurethane‐Based Tissue Adhesive in Arterial Microvascular Anastomoses—A Long‐Term In Vivo Study

Biodegradation and Immunological Parameters of Polyurethane‐Based Tissue Adhesive in Arterial Microvascular Anastomoses—A Long‐Term In Vivo Study

Mussel-Inspired and Bioclickable Peptide Engineered Surface to Combat Thrombosis and Infection

Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease

Contact Info

Product

Resources

About